

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A polypeptide consisting of an immunogenic portion of a native WT1, wherein the polypeptide consists of the polypeptide set forth in SEQ ID NO:144.

2-5. (Canceled)

6. (Currently Amended) A polypeptide ~~according to claim 1~~, wherein the polypeptide consists of 4-9 consecutive amino acids of SEQ ID NO:144.

7. (Currently Amended) A polypeptide ~~according to claim 1~~, wherein the polypeptide consists of 8-9 consecutive amino acids of SEQ ID NO:144.

8-45. (Canceled)

46. (Canceled)

47. (Previously Presented) A composition comprising the polypeptide of claim 1 in combination with a pharmaceutically acceptable carrier or excipient.

48. (Previously Presented) An immunogenic composition comprising the polypeptide of claim 1 in combination with a non-specific immune response enhancer.

49. (Previously Presented) The immunogenic composition according to claim 48 wherein the non-specific immune response enhancer preferentially enhances a T cell response in a patient.

50. (Previously Presented) The composition according to claim 48, wherein the immune response enhancer is selected from the group consisting of Montanide ISA50, Seppic Montanide ISA 720, a cytokine, a microsphere, dimethyl dioctadecyl ammoniumbromide (DDA) based adjuvants, AS-1, AS-2, Ribi Adjuvant system based adjuvant, QS21, saponin based adjuvants, Syntex adjuvant in its microfluidized form, MV, ddMV, immune stimulating complex (iscom) based adjuvants, and inactivated toxins.

51. (Previously Presented) The composition of claim 50, wherein said cytokine comprises GM-CSF.

52.-63. (Canceled)